SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001308179-22-000295
Filing Date
2022-04-28
Accepted
2022-04-28 16:11:26
Documents
6

Document Format Files

Seq Description Document Type Size
1 ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A lrare2022_defa14a.htm DEFA14A 9643
2 GRAPHIC box1.jpg GRAPHIC 1043
3 GRAPHIC checkbox1.jpg GRAPHIC 1493
4 GRAPHIC logo.jpg GRAPHIC 17855
5 GRAPHIC lrare-notice1.jpg GRAPHIC 353722
6 GRAPHIC lrare-notice2.jpg GRAPHIC 204563
  Complete submission text file 0001308179-22-000295.txt   808243
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36276 | Film No.: 22866643
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences